Zhou, Yan <br/><br/>
Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice.  [electronic resource] 

 -  Brain research  12 2019 
 - 146410 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1872-6240 
<br/><br/><label>Standard No.: </label>10.1016/j.brainres.2019.146410  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alcohol Drinking--drug therapy<br/>Alcoholism--drug therapy<br/>Analgesics, Opioid--pharmacology<br/>Animals<br/>Drinking--drug effects<br/>Ethanol--pharmacology<br/>Female<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Morphinans--metabolism<br/>Naltrexone--metabolism<br/>Narcotic Antagonists--pharmacology<br/>Receptors, Opioid, kappa--agonists<br/>Receptors, Opioid, mu--metabolism<br/>Recurrence<br/>Secondary Prevention--methods<br/>Spiro Compounds--metabolism